Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) dropped 3.7% on Wednesday . The stock traded as low as $8.50 and last traded at $8.58, with a volume of 120,588 shares changing hands. The stock had previously closed at $8.91.

Separately, Leerink Swann restated a “buy” rating on shares of Adaptimmune Therapeutics PLC – in a report on Sunday, April 24th. Six research analysts have rated the stock with a buy rating, Adaptimmune Therapeutics PLC – has an average rating of “Buy” and an average target price of $15.63.

The firm’s 50 day moving average is $9.49 and its 200 day moving average is $8.94. The company’s market capitalization is $596.01 million.

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) last announced its quarterly earnings data on Thursday, May 12th. The company reported ($0.22) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.03. On average, equities analysts predict that Adaptimmune Therapeutics PLC – will post ($1.29) earnings per share for the current fiscal year.

In other Adaptimmune Therapeutics PLC – news, Director Charles Elliott Sigal acquired 45,000 shares of the stock in a transaction dated Wednesday, May 18th. The shares were acquired at an average cost of $1.53 per share, for a total transaction of $68,850.00. Following the completion of the transaction, the director now directly owns 52,938 shares of the company’s stock, valued at $80,995.14. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Orbimed Advisors Llc acquired 1,712,400 shares of the stock in a transaction dated Tuesday, May 24th. The stock was acquired at an average price of $10.42 per share, for a total transaction of $17,843,208.00. The disclosure for this purchase can be found here.

Several large investors have recently modified their holdings of ADAP. Jennison Associates LLC boosted its stake in shares of Adaptimmune Therapeutics PLC – by 0.3% in the fourth quarter. Jennison Associates LLC now owns 486,948 shares of the company’s stock valued at $5,873,000 after buying an additional 1,547 shares during the period. Tekla Capital Management LLC boosted its stake in shares of Adaptimmune Therapeutics PLC – by 5.3% in the fourth quarter. Tekla Capital Management LLC now owns 296,934 shares of the company’s stock valued at $3,581,000 after buying an additional 15,000 shares during the period. Finally, Marshall Wace LLP purchased a new stake in shares of Adaptimmune Therapeutics PLC – during the fourth quarter valued at about $1,700,000.

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.